---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-005136"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T18:04:30.844846+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Palatin presents preclinical data for PL9588 glaucoma candidate at ARVO; shows IOP reduction in rabbits

## Summary
- Topically administered PL9588 reduced intraocular pressure (IOP) in normotensive rabbits.
- IOP reduction magnitude similar or greater than FDA-approved drugs latanoprost and timolol.
- Single topical dose of PL9588 lowered IOP for 24 hours.
- PL9588 is a melanocortin agonist; data supports continued development for once-daily glaucoma treatment.
- Company plans to move into clinical development pending available resources.

## SEC filing metadata
- accession: 0001654954-23-005136
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495423005136/0001654954-23-005136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495423005136/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-005136
- JSON: https://secwatch.observer/filing/0001654954-23-005136.json
- Plain text: https://secwatch.observer/filing/0001654954-23-005136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.